natgillin/translations-raw huggingface dataset:
Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 ml/min.
Analize na populaciji so pokazale, da bi bil pri bolniku z očistkom kreatinina 20 ml/min (težka ledvična okvara) ali 50 ml/min (zmerna okvara) ustrezni napovedani očistek zoledronske kisline 37% oziroma 72% tistega pri bolniku, ki bi imel očistek kreatinina 84 ml/min.
Population based analysis demonstrates that age across the range tested (21–75 years) does not significantly alter the pharmacokinetics of Caelyx.
Populacijska analiza kaže, da starost v preskušanem razponu (21 do 75 let) bistveno ne spremeni farmakokinetike zdravila Caelyx.
Population estimated mean volume of distribution at steady-state (Vss/F) of osimertinib is 986 L indicating extensive distribution into tissue.
Populacijsko ocenjen povprečni volumen porazdelitve osimertiniba v stanju dinamičnega ravnovesja (Vss/F) je 986 l; to kaže na obsežno porazdelitev v tkiva.
Population pharmacokinetic (PK) analyses of pasireotide intramuscular use suggest that race does not influence PK parameters.
Analiza populacijske farmakokinetike pasireotida za intramuskularno uporabo kaže, da rasa ne vpliva na farmakokinetične parametre.
Population pharmacokinetic analyses did not detect any effect of MTX, non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids on tocilizumab clearance.
Analize populacijske farmakokinetike niso odkrile, da bi metotreksat, nesteroidna protivnetna zdravila ali kortikosteroidi vplivali na očistek tocilizumaba.
Population pharmacokinetic analyses in patients with advanced cancer (including advanced RCC) and healthy volunteers indicate that there are no clinically relevant effects of age, gender, body weight, race, renal function, UGT1A1 genotype, or CYP2C19 genotype.
Analize populacijske farmakokinetike pri bolnikih z napredovalim rakavim obolenjem (vključno z napredovalim RCC) in pri zdravih prostovoljcih kažejo, da ni nobenih klinično pomembnih vplivov starosti, spola, telesne mase, delovanja ledvic, UGT1A1 genotipa oziroma CYP2C19 genotipa.
Population pharmacokinetic analyses in patients with Ph + leukaemia or malignant solid tumour indicate that there are no clinically relevant effects of age, gender, body weight, race.
Populacijske farmakokinetične analize pri bolnikih s Ph+ levkemijo ali z malignimi solidnimi tumorji je pokazala, da starost, spol, telesna masa in rasa nimajo klinično pomembnih vplivov.
Population pharmacokinetic analyses indicate that body weight (33- 135 kg), gender, race and type of haematological malignancy (MM, MDS or MCL) do not have a clinically relevant effect on lenalidomide clearance in adult patients.
Analize populacijske farmakokinetike kažejo, da telesna masa (33-135 kg), spol, rasa in vrsta hematološke malignosti (MM, MDS ali MCL) nimajo klinično pomembnega vpliva na očistek lenalidomida pri odraslih bolnikih.
Population pharmacokinetic analyses indicate that the oral absorption rate of lenalidomide is similar among MM, MDS and MCL patients.
Analize populacijske farmakokinetike kažejo, da je hitrost peroralne absorpcije lenalidomida pri bolnikih z MM, MDS in MCL podobna.
Population pharmacokinetic analyses indicate that vedolizumab has a total body clearance of approximately 0.157 L/day and a serum half-life of 25 days.
Analize populacijske farmakokinetike kažejo, da celoten telesni očistek vedolizumaba znaša približno 0,157 l/dan, razpolovni čas v serumu pa 25 dni.
Population pharmacokinetic analyses indicated that sunitinib apparent clearance (CL/F) was not affected by creatinine clearance within the range evaluated (42 - 347 ml/min).
Analize populacijske farmakokinetike so pokazale, da se navidezni očistek sunitiniba v območju ocenjevanega delovanja ledvic (očistek kreatinina od 42 do 347 ml/min) ne spremeni.
Population pharmacokinetic analyses indicated that the pharmacokinetics of reslizumab is not significantly different between ethnic groups (white, black and Asian).
Analize populacijske farmakokinetike kažejo, da med etničnimi skupinami (belci, temnopolti in Azijci) ni značilnih razlik v farmakokinetiki reslizumaba.
Population pharmacokinetic analyses of demographic data indicate that no starting dose adjustments are necessary for weight or Eastern Cooperative Oncology Group (ECOG) performance status.
Populacijske farmakokinetične analize demografskih podatkov kažejo, da začetnega odmerka ni treba prilagajati glede na telesno maso ali stanje zmogljivosti, ocenjeni po lestvici ECOG (Eastern Cooperative Oncology Group).
Population pharmacokinetic analyses showed that the pomalidomide pharmacokinetic parameters were not remarkably affected in renally impaired patients (defined by creatinine clearance or estimated glomerular filtration rate [eGFR]) compared to patients with normal renal function (CrCl ≥60 mL/minute).
Populacijske farmakokinetične analize so pokazale, da pri bolnikih z okvaro ledvic (opredeljeno z očistkom kreatinina ali ocenjeno hitrostjo glomerulne filtracije [eGFR – estimated glomerular filtration rate]) farmakokinetični parametri pomalidomida niso bili bistveno spremenjeni v primerjavi z bolniki z normalno funkcijo ledvic (CrCl ≥60 ml/minuto).
Population pharmacokinetic analyses suggest that while low albumin, higher body weight, prior treatment with anti-TNF drugs and presence of anti-vedolizumab antibody may increase vedolizumab clearance, the magnitude of their effects is not considered to be clinically relevant.
Analize populacijske farmakokinetike kažejo, da lahko nizka raven albumina, večja telesna masa, predhodno zdravljenje z zaviralci tumorje nekrotizirajočega faktorja (TNF) in prisotnost protiteles proti vedolizumabu povečajo očistek vedolizumaba, vendar pa obseg njihovih učinkov ne velja za klinično pomembnega.
Population pharmacokinetic analyses with data from over 1300 RA patients revealed a trend toward higher apparent clearance of adalimumab with increasing body weight.
Analize populacijske farmakokinetike s podatki za več kot 1.300 bolnikov z revmatoidnim artritisom so pokazale trend k večjemu navideznemu očistku adalimumaba z večanjem telesne teže.
Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis (N = 60), Crohn’s disease (N = 112), juvenile rheumatoid arthritis (N = 117) and Kawasaki disease (N = 16) with an overall age range from 2 months to 17 years indicated that exposure to infliximab was dependent on body weight in a non-linear way.
Analiza populacijske farmakokinetike na podlagi podatkov, pridobljenih pri bolnikih z ulceroznim kolitisom (n = 60), Crohnovo boleznijo (N = 112), juvenilnim revmatoidnim artritisom (N = 117) in boleznijo Kawasaki (N = 16) v starostni skupini od 2 mesecev do 17 let, je pokazala, da je izpostavljenost infliksimabu nelinearno odvisna od telesne mase.
Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis (N=60), Crohn’s disease (N=112), juvenile rheumatoid arthritis (N=117) and Kawasaki disease (N=16) with an overall age range from 2 months to 17 years indicated that exposure to infliximab was dependent on body weight in a non-linear way.
Analiza populacijske farmakokinetike na podlagi podatkov, pridobljenih pri bolnikih z ulceroznim kolitisom (n = 60), Crohnovo boleznijo (N = 112), juvenilnim revmatoidnim artritisom (N = 117) in boleznijo Kawasaki (N = 16) v starostni skupini od 2 mesecev do 17 let, je pokazala, da je izpostavljenost infliksimabu nelinearno odvisna od telesne mase.
Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis (N=60), Crohn’s disease (N=112), juvenile rheumatoid arthritis (N=117) and Kawasaki disease (N=16) with an overall age range from 2 months to 17 years indicated that exposure to infliximab was dependent on body weight in a non-linear way.
Analiza populacijske farmakokinetike na podlagi podatkov, pridobljenih pri bolnikih z ulceroznim kolitisom (n=60), Crohnovo boleznijo (N=112), juvenilnim revmatoidnim artritisom (N=117) in boleznijo Kawasaki (N=16) v starostni skupini od 2 mesecev do 17 let, je pokazala, da je izpostavljenost infliksimabu nelinearno odvisna od telesne mase.
Population pharmacokinetic analysis demonstrated that the mean plasma clearance value after subcutaneous bolus administration was approximately 14% higher in men than in women and approximately 10% higher in subjects < 65 years than in subjects  65 years.
Populacijska farmakokinetična analiza je pokazala, da je bila povprečna vrednost plazemskega očistka po subkutani aplikaciji bolusa približno 14 % večja pri moških kot pri ženskah in približno 10 % večja pri osebah, mlajših od 65 let, kot pri osebah, starih 65 let ali več.
Population pharmacokinetic analysis in HIV infected patients showed that darunavir pharmacokinetics are not considerably different in the age range (18 to 75 years) evaluated in HIV infected patients (n=12, age  65) (see section 4.4).
Populacijska analiza farmakokinetike pri bolnikih okuženih s HIV, je pokazala, da farmakokinetika darunavirja ni bistveno drugačna v razponu starosti, ki so ga proučevali pri bolnikih, okuženih s HIV (od 18 do 75 let) (n=12, starost  65) (glejte poglavje 4.4).
Population pharmacokinetic analysis in HIV infected patients showed that rilpivirine pharmacokinetics are not different across the age range (18 to 78 years) evaluated, with only 2 patients aged 65 years of age or older.
Populacijska farmakokinetična analiza bolnikov, okuženih z virusom HIV, je pokazala, da se farmakokinetika rilpivirina ne razlikuje glede na razpon ocenjene starosti (18 do 78 let), s samo 2 bolnikoma, starima 65 let ali več.
Population pharmacokinetic analysis in special populations
Populacijska farmakokinetična analiza pri posebnih populacijah
Population pharmacokinetic analysis indicated no appreciable differences in evolocumab serum concentrations in hypercholesterolaemic patients (non-familial hypercholesterolaemia or familial hypercholesterolaemia) taking concomitant statins.
Populacijska farmakokinetična analiza ni pokazala opaznih razlik v koncentraciji evolokumaba v serumu pri bolnikih s hiperholesterolemijo (nedružinsko ali družinsko), ki so sočasno jemali statine.
Population pharmacokinetic analysis indicated that hepatitis B and/or C virus co-infection had no clinically relevant effect on the exposure to rilpivirine.
Rezultati analize populacijske farmakokinetike kažejo, da sočasna okužba z virusom hepatitisa B in/ali C nima klinično pomembnega vpliva na izpostavljenost rilpivirinu.
Population pharmacokinetic analysis of abatacept serum concentration data from patients with JIA 6 to 17 years of age following administration of abatacept 10 mg/kg revealed that the estimated clearance of abatacept, when normalized for baseline body weight, was higher in JIA patients (0.4 mL/h/kg for a child weighing 40 kg) versus adult rheumatoid arthritis patients.
Na osnovi podatkov o serumski koncentraciji abatacepta pri bolnikih z juvenilnim idiopatskim artritisom, starih od 6 do 17 let, po aplikaciji abatacepta v odmerku 10 mg/kg, je analiza populacijske farmakokinetike pokazala, da je vrednost ocenjenega očistka abatacepta, po normalizaciji na izhodiščno telesno maso, pri bolnikih z juvenilnim idiopatskim artritisom večja (0,4 ml/uro/kg za otroke s telesno maso 40 kg) kot pri odraslih bolnikih z revmatoidnim artritisom.
Population pharmacokinetic analysis of data from clinical studies identified race (categories “other” [patients who are not white, black or Asian] and “black”) as a statistically significant covariate on daclatasvir apparent oral clearance (CL/F) and apparent volume of distribution (Vc/F) resulting in slightly higher exposures compared to white patients, but the magnitude of the effect on daclatasvir exposure is not clinically important.
Analiza podatkov populacijske farmakokinetike iz kliničnih študij kaže, da je rasa (kategoriji “drugi” [bolniki, ki niso belci, črnci ali Azijci] in “črni”) statistično pomembna kovariata za navidezni peroralni očistek daklatasvirja (CL/F) in navidezni volumen porazdelitve (Vc/F), pri čemer so bile izpostavljenosti nekoliko višje v primerjavi z bolniki bele rase, obseg učinka na izpostavljenost daklatasvirju pa ni bil klinično pomemben.
Population pharmacokinetic analysis showed that secukinumab was absorbed with an average absolute bioavailability of 73% in patients with plaque psoriasis.
Rezultati analize populacijske farmakokinetike so pokazali, da se pri bolnikih s psoriazo s plaki sekukinumab absorbira s povprečno biološko uporabnostjo 73%.
Population pharmacokinetic analysis suggested age, gender, and race had no effect on the pharmacokinetics of necitumumab, while CL and volume of distribution had a less than proportional positive correlation with body weight.
Analiza populacijske farmakokinetike je nakazala, da starost, spol in rasa niso vplivali na farmakokinetiko necitumumaba, očistek (CL) in porazdelitveni volumen pa sta imela manj kot sorazmerno pozitivno korelacijo s telesno maso.
Population pharmacokinetic analysis suggests that based on Cmax and AUC, 90% of steady state in Cushing’s disease patients is reached after approximately 1.5 and 15 days, respectively.
Analiza populacijske farmakokinetike kaže, da na osnovi Cmax in AUC pride pri 90 % bolnikov s Cushingovo boleznijo do stanja dinamičnega ravnovesja po približno 1,5 oziroma 15 dneh.
Population pharmacokinetic analysis suggests that body mass index (BMI) has no significant effect on the pharmacokinetics of liraglutide.
Populacijska farmakokinetična analiza kaže, da indeks telesne mase (BMI) ne vpliva bistveno na farmakokinetiko liraglutida.
Population pharmacokinetic data from adult and paediatric patients suggest that patients with stable moderate renal impairment (creatinine clearance 30 – < 60 ml/min) receiving a 50% dose reduction achieve similar clofarabine exposure to those with normal renal function receiving a standard dose.
Populacijski farmakokinetični podatki, pridobljeni pri odraslih in pediatričnih bolnikih, kažejo, da bolniki s stabilno zmerno okvaro ledvic (kreatininski očistek 30 – <60 ml/min), ki prejemajo za 50 % manjši odmerek, dosežejo podobno izpostavljenost klofarabinu kot bolniki z normalnim ledvičnim delovanjem, ki prejemajo standardni odmerek.
Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.
Populacijska farmakokinetična raziskava peroralnega aripiprazola ni pokazala klinično pomembnih vplivov kajenja na farmakokinetiko aripiprazola.
Population pharmacokinetic model simulations showed that a starting dose of 7 mg/m2 would be necessary to attain Cmin within the 5 to 15 ng/ml range in patients younger than 3 years of age.
Simulacija s populacijskim modelom farmakokinetike je pokazala, da je pri bolnikih, ki so stari manj kot 3 leta, za doseganje vrednosti Cmin v okviru od 5 do 15 ng/ml potreben začetni odmerek 7 mg/m2.
Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with ADENURIC 40-240 mg QD.
Analize populacijske farmakokinetike/farmakodinamike so bile izvedene pri 211 bolnikih s hiperurikemijo in protinom, zdravljenih z zdravilom ADENURIC 40-240 mg enkrat na dan.
Population pharmacokinetic/pharmacodynamic modelling demonstrated that the reduction of total and tonic-atonic seizure frequencies, the improvement of the global evaluation of seizure severity and the increase in probability of reduction of seizure frequency were dependent on rufinamide concentrations.
Populacijsko modeliranje farmakokinetike/farmakodinamike je pokazalo, da je bilo zmanjšanje pogostnosti vseh napadov in tonično-kloničnih napadov, izboljšanje globalne ocene teže napadov in zvečanje verjetnosti zmanjšanja pogostnosti napadov odvisno od koncentracij rufinamida.
Population pharmacokinetics analysis in HCV infected subjects indicated that cirrhosis had no clinically relevant effect on the exposure to sofosbuvir and GS-331007.
Analiza populacijske farmakokinetike pri osebah, okuženih s HCV, je pokazala, da ciroza ni imela klinično pomembnega učinka na izpostavljenost sofosbuvirju in GS-331007.
Population pharmacokinetics analysis of HIV-infected patients in Phase 2 and Phase 3 studies of Genvoya showed that within the age range studied (12 to 82 years), age did not have a clinically relevant effect on exposures of tenofovir alafenamide.
Populacijska farmakokinetična analiza bolnikov, okuženih s HIV, v študijah z zdravilom Genvoya faze 2 in faze 3, je pokazala, da znotraj preučenega razpona starosti (12 do 82 let) starost ni imela klinično pomembnega učinka na izpostavljenost alafenamidtenofoviratu.
Population pharmacokinetics modeling indicated that the dose of 2.0 mg/kg twice a day provides the same steady- state average plasma concentration as in adults receiving 100 mg twice daily.
Modeliranje populacijske farmakokinetike je pokazalo, da je odmerek 2,0 mg/kg dvakrat na dan povzročil enako povprečno plazemsko koncentracijo v dinamičnem ravnovesju kot pri odraslih, ki so prejemali 100 mg dvakrat na dan.
Population pharmocokinetic analysis in special populations
Analiza populacijske farmakokinetike pri posebnih populacijah
Population pharmocokinetic analysis in special populations
Analiza populacijske farmokokinetike pri posebnih populacijah
Population PK analyses of a pooled dataset from adult patients with GIST and solid tumours and paediatric patients with solid tumours were completed.
Izvedli so populacijske farmakokinetične analize združenih zbirk podatkov, pridobljenih pri odraslih bolnikih z GIST in čvrstimi tumorji ter pediatričnih bolnikih s čvrstimi tumorji.
Population PK analysis indicated that body weight was a significant covariate with a -20% to +30% change in osimertinib AUCss expected across a body weight range of 90kg to 43kg respectively (95% to 5% quantiles) when compared to the AUCss for the median body weight of 62 kg.
Populacijska farmakokinetična analiza je pokazala, da je telesna masa pomembna sospremenljivka: ugotovili so od -20 % do +30 % spremembo AUCss osimertiniba, pričakovano v razponu telesne mase od 90 kg do 43 kg (95 % do 5 % kvantil) v primerjavi z AUCss za mediano telesno maso 62 kg.
Population PK modeling demonstrated that a dose of 10 mg/kg in children less than 4 month of age would be sufficient to achieve the target exposure for the treatment of CNS Candida infections.
FK model populacije je pokazal, da bi bil odmerek 10 mg/kg pri otrocih, mlajših od 4 mesecev, zadosten za dosego ciljne izpostavljenosti potrebne za zdravljenje okužbe z glivami Candida v CŽS.
Population PK modeling demonstrated that a dose of 10 mg/kg in children less than 4 month of age would be sufficient to achieve the target exposure for the treatment of CNS Candida infections.
FK model populacije je pokazal, da bi bil odmerek 10 mg/kg pri otrocih, mlajših od 4 mesecev, zadosten za dosego ciljne izpostavljenosti, potrebne za zdravljenje okužbe z glivami Candida v CŽS.
Population PK modeling indicates that exposure approximately doubles in patients with severe renal impairment (CrCL 15 – 29 mL/min) relative to patients with normal renal function.
Populacijsko FK modeliranje kaže, da se v primerjavi z bolniki z normalno funkcijo ledvic izpostavljenost pri bolnikih s hudo okvaro ledvic (CrCL 15 – 29 ml/min) približno podvoji.
Population PK models developed from studies in patients with Parkinson’s disease indicate that the pharmacokinetic and pharmacodynamics effects of safinamide were not dependent on age, gender, weight, renal function and exposure to levodopa, indicating that dose adjustments will not be required based on these variables.
Populacijski farmakokinetični (PK) modeli, ki so jih razvili na podlagi študij pri bolnikih s parkinsonovo boleznijo, kažejo, da farmakokinetični in farmakodinamični učinki safinamida niso odvisni od starosti, spola, telesne mase, delovanja ledvic in izpostavljenosti levodopi, kar nakazuje, da prilagajanje odmerkov na podlagi teh spremenljivk ne bo potrebno.
population was 44 % with a median event-free survival of 4.6 months, which was similar to the results for the progression-free survival.
Mediana vrednost preživetja brez sopojavov je bila 4,6 mesecev, kar je podobno izsledkom za preživetje brez napredovanja bolezni.
populatione n=668
0,695 (0,567; 0,852)
populationg n=667
(24,7; 31,1)
populationg n=667
populacijag n = 667
Populations not studied
Neraziskane skupine bolnikov
Populations not studied
Populacije, ki niso bile preučevane
Porcilis AR-T DF is a suspension for injection which contains a non-toxic recombinant derivative (see ‘How does Porcilis AR-T DF work?’) of the Pasteurella multocida toxin and inactivated Bordetella bronchiseptica cells.
Zdravilo Porcilis AR-T DF je suspenzija za injiciranje, ki vsebuje netoksični rekombinantni derivat (glej „Kako zdravilo Porcilis AR-T DF deluje? ) toksina Pasteurella multocida in inaktiviranih celic Bordetella bronchiseptica.
Porcilis AR-T DF suspension for injection for pigs
Porcilis AR-T DF, suspenzija za injiciranje za prašiče
Porcilis ColiClos suspension for injection Pig pictogram
Porcilis ColiClos suspenzija za injiciranje Piktogram prašiča
Porcilis PCV emulsion for injection
Porcilis PCV emulzija za injiciranje
Porcilis PCV emulsion for injection for pigs
Porcilis PCV, emulzija za injiciranje za prašiče
Porcilis PCV ID emulsion for injection for pigs
Porcilis PCV ID emulzija za injiciranje za prašiče
Porcilis PCV ID emulsion for injection, for pigs
Porcilis PCV ID emulzija za injiciranje za prašiče
Porcilis PCV M Hyo [a clear pictogram of a pig]
Porcilis PCV M Hyo [piktogram prašiča]
Porcilis PCV M Hyo contains the adjuvants light mineral oil and aluminium hydroxide to enhance the immune response.
Zdravilo Porcilis PCV M Hyo lahko vsebuje tudi mineralno olje in aluminijev hidroksid, ki povečata imunski odziv.
Porcilis PCV M Hyo is a vaccine.
Porcilis PCV M Hyo je cepivo.
Porcilis PCV M Hyo is a veterinary vaccine that contains porcine circovirus type 2 (PCV2) subunit antigen and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.
Porcilis PCV M Hyo je cepivo za uporabo v veterinarski medicini, ki vsebuje podenoto antigena prašičjega cirkovirusa tipa 2 (PCV2) in inaktiviran (neživ) sev bakterije Mycoplasma hyopneumoniae.
Porcilis PCV M Hyo is available as an emulsion for injection.
Cepivo Porcilis PCV M Hyo je na voljo v obliki emulzije za injiciranje.
Porcilis Pesti contains an antigen – E2 (a substance that stimulates an immune response) to CSF.
Zdravilo Porcilis Pesti vsebuje antigen – E2 (snov, ki spodbuja imunski odziv) proti KPK.
Porcilis Pesti contains Classical Swine Fever Virus -E2 subunit antigen.
Zdravilo Porcilis Pesti vsebuje virus klasične prašičje kuge – antigenska podenota E2.
Porcilis Pesti emulsion for injection for pigs
Porcilis Pesti emulzija za injiciranje za prašiče
Porcilis Pesti emulsion for injection for pigs
Porcilis Pesti, emulzija za injiciranje za prašiče
Porcilis Porcoli Diluvac Forte suspension for injection
Porcilis Porcoli Diluvac Forte suspenzija za injiciranje
Porcine
antibiotik
Porcine
Tildipirozin
Porcine circovirus 2
Prašičji cirkovirus 2
Porcine circovirus and porcine enzootic pneumonia vaccine (inactivated)
Inaktivirano cepivo proti prašičjemu cirkovirusu in prašičji enzootski pljučnici
Porcine Circovirus recombinant virus (cPCV) 1-2, inactivated
Prašičji cirkovirus, rekombinantni virus (cPCV) 1-2, inaktiviran
Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty breathing, pale skin and jaundice (yellowing of the skin).
Okužbe s prašičjim cirkovirusom tipa 2 (PCV2) se kažejo s kliničnimi znaki, kot so zmanjšanje telesne mase ali zastoj rasti, povečane bezgavke, oteženo dihanje, bleda koža in zlatenica (rumeno obarvanje kože).